FDA Grants Fast Track Designation to Cocrystal Pharma’s CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational antiviral drug, CDI-988. The treatment is being developed for both the prevention and treatment of norovirus infections, a highly contagious virus responsible for acute gastroenteritis outbreaks worldwide. This designation aims to expedite the development and review process of drugs that address serious conditions and fulfill unmet medical needs.

CDI-988 is an oral antiviral candidate designed to target norovirus infections, which currently lack any approved vaccines or treatments. Norovirus is a leading cause of viral gastroenteritis globally, affecting millions annually with symptoms such as vomiting, diarrhea, and abdominal pain. Cocrystal Pharma stated that this designation will allow for more frequent interactions with the FDA throughout the drug development process and could potentially lead to faster approval timelines if clinical trials demonstrate safety and efficacy.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI